Lmcg Investments LLC Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN

Lmcg Investments LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 132.0% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 33,597 shares of the biopharmaceutical company’s stock after purchasing an additional 19,116 shares during the period. Regeneron Pharmaceuticals accounts for approximately 1.1% of Lmcg Investments LLC’s portfolio, making the stock its 22nd biggest holding. Lmcg Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $17,638,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. E Fund Management Hong Kong Co. Ltd. lifted its holdings in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Activest Wealth Management raised its holdings in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the period. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Saudi Central Bank purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $27,000. Finally, Colonial Trust Advisors purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $32,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on REGN shares. Jefferies Financial Group lifted their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Sanford C. Bernstein lifted their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Citigroup reiterated a “buy” rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Royal Bank Of Canada lifted their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a report on Monday, August 4th. Finally, Raymond James Financial raised Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $817.46.

Regeneron Pharmaceuticals Stock Down 0.9%

Shares of NASDAQ:REGN opened at $564.63 on Friday. The business has a 50-day moving average price of $573.95 and a 200 day moving average price of $565.04. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $59.85 billion, a price-to-earnings ratio of 14.23, a PEG ratio of 1.82 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,024.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The company had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals’s revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company posted $11.56 EPS. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.